NCT06503237View on ClinicalTrials.gov

Safety and Efficacy of SWK002 in Patients With D2T-Rheumatoid Arthritis

NARecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 9, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Anti-CD19 CART cells will be given IV at split doses.

Split intravenous infusion of Anti-CD19 CART cells of (Dose escalating infusion of 1 - 6 x10\^6 CART cells/kg).

Trial Locations (1)

410119

RECRUITING

Hunan Siweikang Therapeutic Co.Ltd, Changsha

All Listed Sponsors
lead

The First Affiliated Hospital of University of Science and Technology of China

OTHER